As both IL-17 and IL-36-mediated inflammatory axis play a critical role in skin inflammation, evident by successful treatment of their corresponding skin inflammatory diseases and interplay of two cytokines in skin inflammation (37–39), we envisage that dual blockade of IL-17A and IL-36R could have enhanced potency to disrupt the IL-17 and IL-36 inflammatory loop to broaden the treatment indications for both targets. This evidence concerns the gene IL17A and inflammatory skin disease.